Ferring Pharmaceuticals adds two products to its robust reproductive health portfolio in the U.S.

Ferring Pharmaceuticals (US) (Ferring) announced today an exclusive agreement to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd. (Sun Pharma). With the addition of Ganirelix, Ferring continues to offer the most complete reproductive medicine portfolio available, which includes MENOPUR^® (menotropins for injection), NOVAREL^® (chorionic gonadotropin for injection, USP) and ENDOMETRIN^® (progesterone) Vaginal Insert.

Ganirelix is a GnRH antagonist used to prevent premature luteinizing hormone (LH) surges in women undergoing fertility treatment. On November 30, 2018, Sun Pharma received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.

"When beginning a treatment process as individualized and complex as fertility, it is critical that patients and providers have a wide variety of treatment options available," says reproductive endocrinologist Gaurang Daftary, MD, MBA, Senior Medical Director, Reproductive Medicine and Women's Health at Ferring and adjunct professor in reproductive endocrinology at the Mayo Clinic and the Yale University School of Medicine, "With the addition of Ganirelix, Ferring continues to provide reproductive endocrinologists in the US with the most comprehensive suite of medications to support the in vitro fertilization process for patients."

Intravaginal Culture (IVC) System, which comprises the INVOcell Culture Device and Retention Device.¹The INVOcell Culture Device uses a woman's own body as an incubator during fertilization and early embryo development. In 2015, INVO Bioscience received FDA clearance for the INVOcell IVC system, making it the first IVC system marketed in the US.

Through this acquisition, Ferring will use its resources and expertise in the field of assisted reproductive technologies (ART) to help reproductive endocrinology practices across the country expand their service offerings to include the IVC procedure, in addition to their current treatment offerings of intrauterine insemination (IUI) and in vitro fertilization (IVF).

In the US, statistics show that over 1.4 million women may benefit from advanced fertility treatment. However, only approximately 130,000 people begin such treatment.²

"Helping people to build families is at the heart of what we do at Ferring and as the leader in reproductive medicine, we will help shape the future of fertility," says Paul Navarre, CEO, Ferring Pharmaceuticals (US). "I am thrilled to welcome two new products to the Ferring family. With Ganirelix, Ferring has added another proven treatment to what is already the most comprehensive reproductive health portfolio available. And with INVOcell, we will further expand treatment options for women and their healthcare providers."

Register as Visitor to CPhI China 2019!